FTI-2148 Inhibitor – Ditfa

98%

Powder: -2 degree C for 3 years
In solvent: -80 degree C for 2 years

680.62

OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CSCC[C@H](NC(=O)c1ccc(CNCc2c[nH]cn2)cc1-c1ccccc1C)C(O)=O

C28H30F6N4O7S

817586-01-9

Others
GGT-1: 1.7uM, FT-1: 1.4nM

(<1mg/mL refers to the product slightly soluble or insoluble)

FTI-2148 (subcutaneous injection; 100mg/kg/day; 14 days) results in breast tumor regression in a ras transgenic mouse model. FTI-2148 (subcutaneous injection; 100mg/kg/day; 4 days) results in 85-88% inhibition of FTase with no inhibition of GGTase I enzymatic activity in breast tumors from mice in vivo settings.FTI-2148 (intraperitoneal injection; 25 or 50 mpk/day with a mini-uMp; started on day 15 and stopped on day 45 and restarted day 53-83) inhibits the tumor growth by 91% in Human lung adenocarcinoma A-549 cells induced mouse model. FTI-2148 (subcutaneous injection; 25 mpk/day with a mini-uMp; 14 days) inhibits tumor growth by 77%by the end of the 2-week treatment in Human Xenograft Nude Mouse Model.